Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Adaptimmune Therapeutics PLC changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 81 | 1 | 80 | 0 |
| Shares | 151.7M | 525 | 124.4M | −27.3M (−18.0%) |
| Value | $144.1M | $499 | $67.0M | −$77.1M (−53.5%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Seas Capital LP | 14,835,146 | $7.99M | 0.94% |
| Acadian Asset Management LLC | 510,216 | $269.0K | 0.00% |
| Citadel Advisors LLC | 175,052 | $94.3K | 0.00% |
| HRT Financial LP | 83,199 | $44.0K | 0.00% |
| Raymond James Financial Inc | 31,081 | $16.7K | 0.00% |
| Legacy Capital Wealth Management, LLC | 27,080 | $14.6K | 0.01% |
| Kingswood Wealth Advisors, LLC | 18,690 | $10.1K | 0.00% |
| Clear Harbor Asset Management, LLC | 18,525 | $9.98K | 0.00% |
| PKS Advisory Services, LLC | 17,000 | $9.16K | 0.00% |
| Squarepoint Ops LLC | 16,563 | $8.92K | 0.00% |
| Baader Bank INC | 18,095 | $8.73K | 0.00% |
| R Squared Ltd | 8,770 | $4.72K | 0.00% |
| Raiffeisen Bank International AG | 907 | $520 | 0.00% |
| Transce3nd, LLC | 175 | $94 | 0.00% |
Sold out (14)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Matrix Capital Management Company, LP | 37,681,515 | $35.8M |
| DAFNA Capital Management LLC | 341,064 | $324.1K |
| Gsa Capital Partners LLP | 99,662 | $95.0K |
| Janney Montgomery Scott LLC | 30,000 | $29.0K |
| DLK Investment Management, LLC | 30,512 | $29.0K |
| IFG Advisory, LLC | 27,500 | $26.1K |
| Fullcircle Wealth LLC | 35,000 | $25.8K |
| Ballentine Partners, LLC | 16,758 | $15.9K |
| Commonwealth Equity Services, LLC | 13,433 | $13.0K |
| Quadrant Capital Group LLC | 12,280 | $11.7K |
| Greenleaf Trust | 11,856 | $11.3K |
| Signaturefd, LLC | 6,620 | $6.29K |
| Northwestern Mutual Wealth Management Co | 69 | $66 |
| Simplex Trading, LLC | 1,052 | $0 |
Not filed for Q4 2024 yet (1)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Carmichael Hill & Associates, Inc. | 525 | $499 |